The mas­ter deal­mak­er is back: David Hung takes the helm at Vivek Ra­maswamy's Ax­o­vant

David Hung earned his spurs as a mas­ter deal­mak­er in biotech, blaz­ing through a string of ma­jor part­ner­ships for good (and bad) drugs be­fore sell­ing Medi­va­tion at auc­tion for a whop­ping $14 bil­lion. Now he’s back, join­ing hands with one of the bright­est fi­nan­cial en­gi­neers in the busi­ness, as CEO of Vivek Ra­maswamy’s Ax­o­vant.

Ra­maswamy turned heads and raised more than a few eye­brows when he snagged a failed Alzheimer’s drug from Glax­o­SmithK­line for $5 mil­lion up­front and then made it the cen­tral fea­ture in a record-set­ting biotech IPO for Ax­o­vant $AX­ON. Since then, Ra­maswamy has been wheel­ing and deal­ing him­self, set­ting up more com­pa­nies as well as an­oth­er IPO for My­ovant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.